Mirati Reports Positive Topline Data From Phase 2 Study With Adagrasib; Names David Meek CEO

Mirati Therapeutics, Inc. (MRTX) reported positive topline results from the potentially registration-enabling cohort of the phase 2 KRYSTAL-1 study, evaluating adagrasib in patients with KRAS G12C-Mutated advanced non-small cell lung cancer. In the intent-to-treat population, the study showed adagrasib 600mg BID showed an objective response rate of 43% and a disease control rate of 80%. The safety and tolerability profile was consistent with previously reported findings for adagrasib.

Also, the company reported updated findings from the phase 1/1b KRYSTAL-1 study evaluating adagrasib 600mg BID in all 19 patients enrolled with KRASG12C-mutated advanced NSCLC as of the June 15, 2021 data cutoff. The investigator assessed objective response rate was 58% in this study.

The company looks forward to submitting its New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2021.

Separately, Mirati Therapeutics announced the appointment of David Meek as Chief Executive Officer, effective immediately. David Meek most recently served as president, CEO and board member of FerGene. Charles Baum will continue to lead the research and development organization as president, founder and head of R&D.

For comments and feedback contact: editorial@rttnews.com

Follow RTT